New
Automated Nucleic Acid Extraction Workstation SAW-48
BioPerfectus is proud to announce the launch of two new products, which obtained FDA and CE certification: Automated Nucleic Acid Extraction Workstation SAW-48 and Cell Nucleic Acid Extraction Kit (Magnetic Bead Method). These products are designed to automate STD and HPV detection.
Cervical Cancer Screening Solution
With over 600 thousand new cases and more than half that would lead to death yearly, cervical cancer is listed as NO.4 cancer among women worldwide. Lack of screening and treatment leads to higher rates of incidence and mortality. Bioperfectus is confident in providing products, supporting tests for cervical swabs, and liquid-based cytology samples with solid results, enabling women to get access to screening and diagnosis at the early stage of HPV infection before the development of precancerous lesions and cervical cancer.
NEW
BioPerfectus Introduces New Nucleic Acid Extraction Solution
BioPerfectus is proud to announce the release of three new products: Nucleic Acid Extraction System SSNP-A6 (FDA-listed), Nucleic Acid Extraction Rapid Kit 96T (Magnetic Bead Method) and Nucleic Acid Extraction and Purification Rapid Kit 96T.
New
BioPerfectus GI Total PCR Solution is preparing for norovirus detection
BioPerfectus is pleased to launch Norovirus Real Time PCR Kit and Norovirus GI and GII Real Time PCR Kit to safeguard our children with high clinical performance.
New
Zoonotic Infectious Diseases Total PCR Solution
BioPerfectus proudly introduce 13 new members to our Zoonotic Infectious Diseases Total PCR Solution, offering verified products and prompt responses to global health emergencies.
Monkeypox Virus Diagnostic Solution
With increasing confirmed monkeypox cases, more people, countries, and regions are at risk of infection. Nowadays, confirmed cases of infants and cases in schools have been reported; the monkeypox virus has spread among vulnerable individuals, indicating great urgent demand for early diagnosis. Bioperfectus provides FIVE kits for humans with a CE certificate and ONE kit for veterinary use, presenting a rapid response to help diagnose monkeypox infection as early as possible.
SAW-96
SAW-96 is an automated nucleic acid extraction workstation, which integrates sample loading, nucleic acid purification, and PCR setup functions in one instrument. The run duration is less than 70 minutes for 1-96 samples. Based on experienced magnetic separation technology, SAW-96 provides high throughput automation combined with high performance.
Total PCR Solution
Bioperfectus Total PCR Solution offers holistic products of extraction systems, extraction reagents, real-time PCR systems, and RT-PCR reagents. The automatic solution could help customers to establish a highly efficient PCR workflow and release the labor.

Jiangsu Bioperfectus Technologies Co., Ltd.

(SSE:688399)

Since its founding in 2010, BioPerfectus has been dedicated to providing molecular diagnostic solutions specializing in emerging infectious diseases for generations and generations to come. We are leading the change by offering Real-Time PCR Kits, Nucleic Acid Extraction Systems, Automation Solutions, and Rapid Tests to laboratories, hospitals, institutions, and CDCs across the globe. BioPerfectus products have been distributed to more than 100 countries around the world. As one of the leading global IVD suppliers, BioPerfectus is committed to delivering excellent services and products that meet the highest international quality and safety standards. Our global presence enables us to build close relationships with our clients and leverage our expertise to support them worldwide.

62,000 +㎡

An industrial park of over 62,000㎡ integrating fully self-innovative R&D, production, warehousing, logistics, sales, marketing and customer service divisions catering for various business scenarios

800 +

Over 800 Bioperfectus people’s permission gathering the perseverance and determination to fight against the global pandemic

5,000,000 +

Production capacity ramping up to more than 5 million tests/day ensuring the quick sufficient response to infectious diseases

global presence

100 Countries within a year

Bioperfectus Products & Service have been distributed to over 80+ countries around the globe within only one year since the international business established.

280 Global Partners

Product Center
News Center
09-252023
Academy Express | Cost-Effectiveness Analysis of HPV Extended versus Partial Genotyping for Cervical Cancer Screening in Singapore
Academy Express | Cost-Effectiveness Analysis of HPV Extended versus Partial Genotyping for Cervical Cancer Screening in Singapore
09-252023
The elevated risk of a diagnosis of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) with HPV16/18 is well established. Recent evidence suggests that the risk with the 12 other hr-HPV varies across a wide range: with HPV31 (7.98.9%) and HPV33 (5.4%15%) having higher risks than HPV18 (2.79%), thus, warranting a colposcopy. HPV35/39/68/51/56/59/66 with a low-grade squamous intraepithelial lesion (LSIL) or atypical squamous cells of undetermined significance (ASCUS) possess a low risk (2.0%). For patients with these genotypes, unnecessary coloscopies can be avoided. Using extended genotyping (XGT) for cervical cancer screening is crucial for eliminating cervical cancer because increasing the HPV vaccine has shifted the HPV epidemiology. Furthermore, there are geographical differences in specific hrHPV that contribute to invasive cancers. Based on the evidence mentioned above, the team led by Brandon Chua at the National University of Singapore systematically evaluated the pros and cons of conducting HPV extended genotyping screening in the Singapore cervical cancer screening program and published their research findings in "Cancers" under the title "Cost-Effectiveness Analysis of HPV Extended versus Partial Genotyping for Cervical Cancer Screening in Singapore." The study indicates that extended genotyping (XGT) is cost-effective compared to partial genotyping (PGT), utilizes fewer resources, and provides a risk-based approach as the primary cervical cancer screening method. The researchers constructed a discretely integrated condition event (DICE) simulation to evaluate the cost and outcomes of the HPV extended genotyping screening strategy compared to HPV16/18 genotyping screening from the perspective of healthcare payers. A cohort of 500,122 screening candidates was modeled, including unvaccinated screening candidates aged 30-69 years old. The model considers one five-year screening cycle and lifetime outcomes if diagnosed with CIN2+. Screening algorithms and follow-up modeled for PGT and XGT are as follows: The input variables in the model are as follows: The study compared the total cost and quality-adjusted life years (QALYs) loss between the two screening strategies and calculated the Incremental Cost-Effectiveness Ratio (ICER). The research evaluated the cost-effectiveness of the two screening strategies by comparing them to a cost-effectiveness threshold. The cost-effectiveness threshold was taken as Singapore Dollars (SGD) 100,000, comparable to the gross domestic product per capita in Singapore in 2021. Additionally, the researchers conducted a one-way sensitivity analysis to assess the impact of uncertainty in the model inputs. The research indicates: ◎ In a five-year screening cycle, compared to the HPV16/18 genotyping strategy, the use of HPV extended genotyping (XGT) for cervical cancer screening strategy resulted in 7,130 cases (19.4%) fewer colposcopies, 9,787 (1.6%) fewer clinical consultations, and 6,027 (7.0%) fewer cytology tests; yet an additional 2,446 (0.5%) HPV tests, giving 274.42 more Quality-Adjus. This yields an ICER of SGD 16,370/QALY. Hence, XGT was cost-effective compared to PGT, at a willingness-to-pay threshold of SGD 100,000/QALY. ◎ XGT was cost-effective across input ranges in one-way uncertainty analysis, with ICERs ranging between -SGD 17,736/QALY and SGD 50,474/QALY (-USD 21,089/QALY and USD 60,017/QALY). In Singapore, the use of XGT can become the next primary cervical cancer screening method, providing a cost-effective and risk-based approach. Even with improved HPV vaccination coverage over time, XGT should remain valuable in stratifying patients for management based on risk profiles. Reference:Chua B, Lim LM, Ng JSY, Ma Y, Wee HL, Caro JJ. Cost-Effectiveness Analysis of HPV Extended versus Partial Genotyping for Cervical Cancer Screening in Singapore. Cancers (Basel). 2023 Mar 16;15(6):1812. doi: 10.3390/cancers15061812. PMID: 36980698; PMCID: PMC10046888.
09-212023
Empowering Women's Health: Gynecologic Cancer Awareness Month
Empowering Women's Health: Gynecologic Cancer Awareness Month
09-212023
🎗💜September is Gynecologic Cancer Awareness Month! Did you know Gynecologic cancer is not just one type? They include cervical, ovarian, uterine/endometrial, vaginal, and vulvar cancer. Despite being 90% preventable and treatable before reaching a malignant stage, cervical cancer remains the fourth leading cause of cancer-related deaths worldwide.🔍Early detection is one of the strongest defenses against cervical cancer. Specifically, regular Pap tests and HPV tests play a crucial role in detecting cervical cancer early. BioPerfectus extends its focus to the forefront of women's health, with a particular emphasis oncervical cancer screeningand thediagnostics of sexually transmitted diseases (STDs), empowering women to take control of their health. Join us in raising awareness this month. Share this post, schedule a screening, and let's make a difference together in the fight against gynecologic cancers.💕 Learn more: https://foundationforwomenscancer.org/gcam/
09-072023
Academy Express | Human Papillomavirus (HPV) Infection and Its Impact on Male Infertility
Academy Express | Human Papillomavirus (HPV) Infection and Its Impact on Male Infertility
09-072023
Nowadays, the striking numbers of infertile couples that turn to assisted reproductive technologies (ART) drive the research toward a more comprehensive understanding of the underlying causes. Male factors contribute to the inability to conceive in half of the cases, and it has been suggested that sexually transmitted infections could have a role in the onset of spermatozoa impairments. Since the impact of HPV infection on sperm quality and sperm DNA integrity is debated, scholars from Italy analyze its impact on conventional seminal parameters and the sperm DNA fragmentation index (DFI). Methodology: In order to elucidate the contentious impact of HPV infection on in vitro fertilization, it is necessary to meticulously analyze alterations in sperm parameters and DNA integrity. A retrospective observational study was performed on a sample of 117 male partners of HPV-positive women undergoing in vitro fertilization procedures. For each sample, semen parameters were assessed, HPV DNA genotypes were detected by using conventional hybridization methods, and the Sperm Chromatin Dispersion (SCD) test was conducted to evaluate sperm DFI, DNA fragmentation, concentration, motility, and morphology. Conclusion: The results showed a higher rate of HPV-negative patients (59.8% vs. 40.2%) and no HPV-related effect on DFI, sperm concentration, total sperm number, and total motility. Only progressive motility and morphology were found as significantly influenced by HPV positivity. Moreover, we observed a statistically significant difference in DFI when comparing high-risk HPV (HR-HPV) and low-risk HPV (LR-HPV) genotypes. The study data suggest that the presence of any HPV type, whatever the exact localization of the virions, can impair some sperm parameters, while HR-HPVs specifically affect the integrity of spermatozoa DNA. Results 1. Seminal : HPV-Negative vs. HPV-Positive Samples Of the 117 semen samples from male partners of HPV-positive women of infertile couples, 70 were HPV negative (59.8%) and 47 (40.2%) were HPV positive. Patients with HPV semen infection had a mean age of 38.6 8.1 (SD) years, not different from the non-infected subjects. Table 1shows no HPV-related effect on DFI (p-value = 0.32) and no significative differences between the HPV-negative vs. HPV-positive groups in seminal parameters: sperm concentration, total sperm number, and both progressive and total motility. The study also observed a significantly lower rate of normal forms in HPV-positive samples in comparison to HPV-negative samples (p 0.0001). In addition, HPV positivity was significantly associated with head defects (p= 0.0047), neck and midpiece defects (p= 0.0002), and tail defects (p= 0.0033). The relationship between HPV and its negative effect on sperm morphology remains weakly understood, but it could be due to the presence of HPV virions located in the different semen fractions. 2. Seminal Samples Parameter Compared with Lower Reference Limits Figure 2 graphically depicts the percentages of patients with normal scores for semen characteristics, in HPV-positive and -negative groups, compared with lower reference limits (fifth centiles and their 95% confidence intervals). The study observed statistically significant differences in progressive motility (p = 0.0254), immotile spermatozoa (p = 0.0372), and normal forms (p 0.0001). 3. Seminal of HPV-Positive Patients Stratified in Low and High-Risk Table 2 identifies variations in seminal parameters between low- and high-risk genotypes infected samples; a further statistical analysis was performed only on HPV-positive patients. No differences were observed except for DFI (p = 0.0283), which showed a significant increase in the high-risk group. On the contrary, progressive motility and morphology, which varied in relation to HPV positivity, did not show any genotype-related alteration. This data confirmed that the viral presence alone, regardless of the type, produced alterations in the aforementioned parameters. Based on the findings of this study, HPV semen infection, regardless of HPV type and exact location of the virions, significantly impairs spermatozoas progressive motility, morphology, and immotile sperm rate. Conversely, the increased rate of DFI was a genotype-related alteration since it was only observed in HR-HPV-infected samples when compared to LR-HPV-infected ones. This is a crucial result as, to the best of our knowledge, the different influences of HR and LR genotypes on semen parameters and sperm genomic integrity have hardly been analyzed. Reference: Capra, G.etal. Human Papillomavirus (HPV) Infection and Its Impact on Male Infertility. Life 2022, 12, 1919. https://doi.org/10.3390/life12111919.
Service Network
Support is only one step away
A good after-sales service is essential for efficiency of workload in PCR laboratory. Bioperfectus delivers most perfect service via our authorized distributors and global service center. With well-experienced service staff, sufficient spare-part inventory and fast global logistics, Bioperfectus aims to provide with the satisfactory solutions to our end users.We offer 24/7 after-sales service, prompt response and periodical training programs.
CONTACT US NOW